SYNBIOMATICA

Research

Scars in mice cleared only while the scarring cells could still make cAMP

A SCAR INSIDE an organ is built by cells. After an injury, the ordinary support cells of a tissue, called fibroblasts, turn into myofibroblasts, which contract and lay down collagen, the protein that gives a scar its bulk. In healing that goes well, those cells then die off and the collagen is taken away again. In diseases such as idiopathic pulmonary fibrosis and the skin disease scleroderma the cells persist and the scar does not shrink.

A preprint posted on bioRxiv on November 16th asks what the removal depends on. Sean Fortier, Marc Peters-Golden and colleagues at the University of Michigan report that in mice, lung and skin scars that normally fade do not fade if the scarring cells lose the ability to make cAMP, a small messenger molecule a cell produces inside itself when certain receptors on its surface are switched on.

Work in dishes, including earlier work from the same laboratory, had shown that pushing cAMP up turns myofibroblasts back toward ordinary fibroblasts and makes them able to die again. In this paper the authors first went the other way in human lung fibroblasts, using CRISPR to delete GNAS, the gene for the protein a cell needs in order to turn a receptor signal into cAMP. Those cells made far less cAMP when prompted, carried more collagen and more of the muscle-like protein that marks a myofibroblast, and resisted a signal that normally triggers them to die.

The mouse experiment turns on its timing. The authors built a line in which tamoxifen, given in the food, deletes the same gene in collagen-making fibroblasts, including the myofibroblasts that make scar, and tags those cells red so they can be found later. Scarring was started with a single dose of bleomycin into the airway, a model in which lung scarring peaks around day 21 and then clears over the following six weeks. The tamoxifen diet began on day 21, after the scar had already peaked, and ran until the lungs were examined on day 42 or day 63. Deleting the gene only at that point, the authors write, "served to ensure that outcomes can be attributed to the influence of fibroblast-specific cAMP signaling exclusively during the resolution process."

Control animals cleared their scars, losing collagen steadily between day 21 and day 63 by three measures, a chemical assay for collagen, a stain for it in tissue sections and a standard score of how fibrotic a lung looks. The mice whose fibroblasts could no longer make cAMP did not clear theirs. Their lungs still carried collagen and still looked fibrotic at day 63, and at day 42 fewer of their tagged fibroblasts were caught in the act of dying. Reading the genes switched on in single cells showed differences not only in the fibroblasts themselves but also in macrophages, the immune cells that clear debris, and in the cells lining the air sacs. How a change made in fibroblasts reaches those neighbors, the authors say, is an open question.

Skin behaved like lung. In a model of scleroderma made by injecting bleomycin under the skin daily for a week in female mice, the authors started tamoxifen on day 24 and looked on day 63. Control skin thinned again by then, with the fat layer beneath the dermis returning. Skin from mice lacking fibroblast cAMP kept a thicker dermis, more collagen and less of that fat layer.

The authors list several limits. This is a preprint that has not been through peer review. Both models resolve on their own, which human pulmonary fibrosis and scleroderma do not, so the experiment asks what sustains a natural clearance rather than what might start one in a disease that never clears. The bleomycin dose was low, by the authors' own account, which likely limited the fibroblast and lining-cell populations they could see. No single-cell reading was done in the skin, and the authors write that the role of this machinery in human tissue still has to be checked.

The FDA label for Jascayd, Boehringer Ingelheim's nerandomilast, which is approved for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults, says the drug blocks an enzyme that breaks cAMP down and so lifts the amount inside cells, and the preprint did not test it. The mouse result suggests that keeping cAMP high in scarring cells may matter for clearing a scar, which is a different question from slowing its growth.

Sources

  1. Fortier SM, ... Peters-Golden M. Endogenous cAMP production within tissue fibrob
  2. JASCAYD (nerandomilast) tablets, Boehringer Ingelheim, NDA 218764, FDA prescribi
  3. JASCAYD (nerandomilast) label page on DailyMed, SPL set id fa1b14c6-957f-d326-50
  4. Fortier SM, et al. JCI Insight (2021), PMC8026183, on cAMP and myofibroblast ded